

Canadian Perspective

Bryce Kiberd
Medical Lead, MOTP Atlantic Canada
CST Representative

Differences

- No National OPTN or UNOS systems
 - Provincial programs (Gill AJT 2008;8:1580)
- National Standards for Perfusable Organs
 - Canadian Standards Association (www.csa.ca)
 - Initial distribution 2003 and updated 2007
 - Recent Health Canada Audit of all Live Donor programs
 - National Live Donor Paired Exchange Program

Living Donation Standards

- 13.1 Contraindications or Exclusion Criteria
 - 13.1.2 Examples
 - h) Persons at high risk for HIV, HBV or HCV*
- Mandatory standard for high risk
Source document: 1994 CDC criteria
Needs Updating and Risk Quantification

Exceptional Release


- 17.3 Exceptional release/distribution
 - 17.3.2 Based on clinical judgement of the transplanting physician with informed consent of the potential recipient.
 - 17.3.4 Requires authorization by the Medical Director and does not preclude usual practice described in SOP manual.
 - 17.3.6 A report documenting details of the exceptional release (reason, approval, follow up testing, etc)

Standard Screening of Live Donors

- 12.2.3 Assessment of Living Donors
 - 12.2.8 Tests specified in Clause 14.2 shall be performed within one month of surgery.
- 14.2.1 Infectious Disease Testing
 - 14.2.6.3 Minimum (serologic) testing includes HIV, HBV, HCV, and HTLV 1/11

Back to the Case


- The Canadian Regulations
 - Would not have prevented transmission
 - Serology within 1 month
 - But recipient and transplanting physicians would have been informed of increased risk
 - Extra precautions could then have been taken
 - NAT testing, donor counselling, recipient follow up etc.



Proposed recommendations NAT testing within 7 days


My Perspective

- Testing all live average risk donors Canada
 - Low prevalent HIV (0.2%) and HCV (0.8%) population
 - 450 average risk live donors yearly
 - Residual risk of about 1/45,000 by serology
 - Statistically miss 1 infection every 100 years
- Gain with NAT testing likely to be exceedingly small but very expensive




Proposed recommendations NAT testing within 7 days

- Testing increased risk live donors in Canada
 - Very few
 - Requires exceptional release report and recipient **consent**
 - NAT testing may not reduce residual risk of infection in increased risk donor to the level of serologic testing in average risk patients.
- Proposal seems reasonable but a challenge for some centers




Do we have a DTAC Equivalent?



Organ Transplantation Reporting of Errors/Accidents

- Health Canada- Health Products and Food Branch Inspectorate
 - Established in 2007 to minimize potential risks of CTO (Cells Tissues and Organs).




Organ Transplantation Reporting of Errors/Accidents

- Error/Accident reporting
 - Error= deviation from a standard
 - Accident=unexpected event
- Required Actions Outlined
 - Report required with 24 hours with subsequent reports every 15 days until final report



Organ Transplantation Reporting of Adverse Reactions

- Health Canada- Marketed Health Products Directorate
 - Established in 2002 to enhance post market surveillance of drugs, biologics, and devices.
 - To date few reports of adverse events



**Unsure what to do? Call the
BTOX Specialist**

- Canadian BTOX (Blood, Tissues, Organs and Xenografts) unit manager Gita Nayeri (gita.nayeri@hc-sc.gc.ca)
- Contact Information
 - Atlantic Canada
 - Tele 902-426-0748 Fax 902-426-6676
- Documents
 - CTO regulations <http://laws.justice.gc.ca/en/SOR-2007-118>
 - Error Accident Report Form http://www.hc-sc.gc.ca/dhp-mps/compli-conform/info-prod/cell/frm_0172_tc-tm-eng.php